Aggressive ®bromatosis (also called desmoid tumor) occurs as a sporadic lesion or as part of Familial Adenomatous Polyposis, which is caused by germ line mutations in the Adenomatous polyposis Coli (APC) gene. APC is involved in the regulation of the cellular level of beta-catenin, which is a mediator in Wnt signaling. Mutational analysis of the beta-catenin and APC genes was performed in 42 sporadic aggressive ®bromatoses. Nine tumors had mutations in APC, and 22 had a point mutation in beta-catenin at either codon 45 or codon 41 (producing a stabilized beta-catenin protein product). Immunohistochemistry showed an elevated beta-catenin protein level in all tumors, regardless of mutational status. Beta-catenin localized to the nucleus, and was not tyrosine phosphorylated in the six tumors in which this was tested. The demonstration of mutations in two mediators in the Wnt-APCbeta-catenin pathway implicates beta-catenin stabilization as the key factor in the pathogenesis of aggressive ®bromatosis. This is the ®rst demonstration of somatic beta-catenin mutations in a locally invasive, but non metastatic lesion composed of spindle cells, illustrating the importance of beta-catenin stabilization in a variety of cell types and neoplastic processes. Moreover, this tumor has one of the highest reported frequencies of beta-catenin mutations of any tumor type.
Keywords: beta-catenin; aggressive ®bromatosis; mutational analysis; immunohistochemistry; tyrosine phosphorylation Aggressive ®bromatosis (also called desmoid tumor) is a locally invasive soft tissue tumor composed of spindle (®brocyte like) cells. It occurs as a sporadic lesion, or as part of the familial conditions, familial adenomatous polyposis (FAP) and familial in®ltrative ®bromatosis, which are both caused by germ-like mutations in the adenomatous polyposis coli (APC) gene (Eccles et al., 1996; Kinzler et al., 1991) . We, and others, found somatic APC mutations in a subset of sporadic aggressive ®bromatoses (Alman et al., 1997a; Giarola et al., 1998) . One function of the APC gene product is to regulate the cellular level of beta-catenin, which acts in cell adhesion, and is also a mediator in Wnt (Wingless) signaling pathway (Behrens et al., 1998; Papko et al., 1996) . Most APC mutations result in the synthesis of a truncated protein that lacks its beta-catenin regulatory function (Munemitsu et al., 1995) . These APC mutations result in beta-catenin protein accumulation, thus mimicking activation of Wnt signaling. Stabilized beta-catenin can bind to transcription factors in the t-cell factor-lymphoid enhancer factor (Tcf-LEF) family, resulting in transactivation of transcription (Behrens et al., 1996; Morin et al., 1997) .
A sequence encoded by a portion of the third exon of beta-catenin contains serine/threonine residues that are phosphorylated when beta-catenin binds to APC and other proteins (Rubinfeld et al., 1997) . This phosphorylation leads to protein degradation, probably through the ubiquitin-proteosome pathway (Orford et al., 1997) . These mutations form a stabilized form of beta-catenin that can bind Tcf-LEF family members (Rubinfeld et al., 1997) . Beta-catenin also plays an important role at the cell membrane, where it binds to the cadherin cell adhesion molecules. Tyrosine phosphorylation of Beta-catenin occurs at the cell membrane, and is in association with higher cell mobility, e.g. in colonic neoplasia, the level of betacatenin tyrosine phosphorylation is elevated, compared to normal colonic epithelium (Liu et al., 1997; Takayama et al., 1998) .
This study was undertaken to determine if betacatenin mutations are present in sporadic aggressive ®bromatoses. We also determined the incidence of APC mutations in these tumors. Protein level of betacatenin between lesional and normal cells was compared, and it was determined if beta-catenin is tyrosine phosphorylated.
Forty-two sporadic aggressive ®bromatoses, treated and surgically resectioned, were studied. Patients did not have a personal or family history of other ®bromatoses or colonic neoplasia, nor were they treated with adjuvant therapies before the surgical samples were obtained. Normal tissue from the same patients (usually from fascial tissues) were obtained from the surgical resection margin. Cryopreserved tissues were used to extract DNA and RNA for mutational analysis. Formalin ®xed, paran embedded tissues were used for immunohistochemistry. APC mutational status was previously reported in four of the cases (Alman et al., 1997a) .
Twenty-two of 42 samples analysed demonstrated mutations in beta-catenin (Figures 1 and 2 ). Betacatenin was ampli®ed using primers from exon-3 anking introns (sense primer 5'-catttccaatctactaatgct and antisense primer 5'-ctgcattctgactttcagtaa) and primers described by Koch et al. (1999) . SSCP followed by direct sequencing was used to detect mutations. To test complete or partial deletions of exon 3, a PCR ampli®cation was performed using an exon-2 forward primer (5'-ttgaagtataccatacaactg) and an exon-4 reverse primer (5'-gcagcatcaaactgtgtagat), generating a PCR product of 1037 bp. The length of this PCR product was checked by standard agarose gel electrophoresis. Beta-catenin analysis showed a point mutation at two codons, 41 or 45 in 22 cases. Ten resulted in a substitution of alanine for threonine at codon 41 and twelve resulted in a substitution of phenylalanine for serine at codon 45. These substitutions are shown to produce a stabilized beta-catenin protein product (Rubinfeld et al., 1997) . Normal marginal tissues contained a wild-type sequence. The tumors containing a beta-catenin mutation all had a wild-type APC sequence. Figure 1 Results of SSCP for sporadic aggressive ®bromatosis. A 5 ml aliquot of PCR product was mixed with 5 ml of formamide dye (95% formamide, 0.05% bromophenol blue and 0.05% xylene cyanol), denatured at 958C for 3 min and snap-cooled on ice. Aliquotes of 2 ml were analysed on a non-denaturing polyacrylamide gel (10% acrylamide and 2% cross-linking), and run at room temperature. Electrophoresis was performed in 0.56 TBE on vertical gels. Gels were dried on Whatman paper and autoradiography was performed. Several cases showing Thr41 and Ser45 substitutions are illustrated Figure 2 Sequencing results for a portion of exon three from one case of sporadic aggressive ®bromatosis. Ampli®ed products were puri®ed from the primers by gel electrophoresis and the Qiaquick DNA isolation kit (Qiagen). DNA sequences were determined using the dideoxy chain termination method and using¯uorescent dye terminators in an automated DNA sequencer. Both the upstream and downstream primers for PCR ampli®cation were used for sequencing to obtain forward and reverse sequences. Nine of 42 cases showed a mutation in APC (Table  1) . A protein truncation assay was used to detect APC mutations. This was performed using a previously reported technique with PCR primers which ampli®ed the APC gene in ®ve segments, and introduced a T7 promoter sequence into the ampli®ed product (Powell et al., 1993) . Samples demonstrating an abnormal protein electrophoresis pattern were analysed for the sequence of that segment using a series of overlapping primers and an automated sequencer. SSCP was used for exons 1 through 4 in select cases in which sucient RNA was unavailable. Loss of heterozygosity of the APC gene was examined using two extragenic markers D5S134 (GDB 3675) and D5S346 (GDB 60900), and intragenic markers located in exons 6, 11, 15, and the 3' untranslated region of the APC gene. Nine of the lesions contained APC mutations. The APC mutations were clustered between codons 1324 and 1567 and all resulted in an early stop codon. There was a mutation in both alleles in one case, and loss of heterozygosity in six cases. None of the lesions with an APC mutations also contained a beta-catenin mutation. The normal tissues from these cases contained a wild-type APC sequence.
Beta-catenin protein expression was increased in all 42 lesions (Figure 3 ). Formalin ®xed paran embedded material was used to analyse beta-catenin protein expression using immunohistochemistry, as previously described (Alman et al., 1997a) . The slides were blindly graded by a single observer. Cells over ®ve high powered ®elds from the periphery of the lesion were observed for per cent of cells exhibiting staining, pattern of staining (cytoplasmic, membrane, or nuclear), and intensity of staining (Diest et al., 1997). Intensity of staining was graded using a modi®cation of the Histo-score (Bosman et al., 1992) combining scores 2 and 3 into a single score, due to poor reducibility between the intermediate grades (Diest et al., 1996) . Thus, slides were scored as no staining (0), weakly positive (1), positive (2), and very strongly positive (3). Almost all of the tumor cells exhibited cytoplasmic and nuclear staining for beta-catenin in all 42 cases examined. Beta-catenin was also found in almost all the normal ®brocytes, although staining here localized to the cytoplasm or cell membrane. There was greater staining intensity for beta-catenin in cells from the tumors than in cells from normal marginal tissues in each case. The average increase in grade was 0.9, with a mean grade of 2.3 in the tumors and 1.4 in the marginal tissues (P50.05 by the two way Student's ttest).
Confocal microscopy showed that beta-catenin localized strongly to the cell nucleus, and weakly to the cytoplasm in primary cultures from tumor Figure 3 Beta-catenin immunohistochemistry. Formalin ®xed, paran embedded tissues were dewaxed and quenched in hydrogen peroxide/methanol solution, immersed in 10 mmol/l citric acid, and heated for 15 min in a 750-W microwave oven. After washing and blockade with 1% serum bovine albumin, the slides were incubated with monoclonal antibody to beta-catenin (Transduction Laboratories, Lexington, KY, USA) at 10 mg/ml overnight at 408C. Tissues were washed with PBS, incubated with a secondary antimouse immunoglobulin, and detected using immunoperoxidase staining (Vector Laboratories, Burlingame, CA, USA). Tumor and normal marginal tissues were processed at the same time, to avoid slight variations in technique that might alter staining characteristics. Figure  4 ). Cell cultures were established as previously reported (Li et al., 1998) . Three of the tumors examined harbored a beta-catenin mutation, one had an APC mutation, and the other two contained both a wild-type APC and beta-catenin sequence. Betacatenin localized to the cytoplasm and cell membrane in primary cell cultures from normal ®broblasts.
Beta-catenin was not tyrosine phosphorylated in the tumors tested ( Figure 5 ). Fresh tissue was used to determine the tyrosine phosphorylation status of betacatenin in six cases. Three of the tumors examined harbored a beta-catenin mutation, one had an APC mutation, and the other two contained both a wildtype APC and beta-catenin sequence. The cells from the SW480 colon cancer cell line did contain betacatenin in a tyrosine phosphorylated form.
Aggressive ®bromatosis is a unique lesion, as it is locally invasive, but does not metastasize. Previous work, demonstrating that it is a monoclonal lesion, suggests that it is caused by a mutation giving a proliferative advantage to the involved cells (Alman et al., 1997b; Li et al., 1996) . Studies showing that somatic APC mutations are present in a subset of sporadic lesions, suggest that APC plays a role deregulating growth control in the lesion (Alman et al., 1997a; Giarola et al., 1998) . This study shows that most lesions, that do not harbor APC mutations, contain a mutation in beta-catenin, resulting in a stabilized protein product. We also demonstrate elevated beta-catenin protein level in the tumors, regardless of mutational status. This suggests that dysregulation of the Wnt-APC-Beta-catenin signaling cascade plays a key role in the pathogenesis of aggressive ®bromatosis.
The incidence of beta-catenin mutations varies among the tumor types in which they have been identi®ed (Table 2) . Benign lesions such as, aggressive ®bromatosis, pilomatricoma, and hepatoblastoma, have very high rates of beta-catenin stabilizing mutations. This suggests a role for beta-catenin stabilization in benign, but not necessarily premalignant, processes.
The incidence of somatic APC mutation varies widely between the two previous reports (Alman et al., 1997a; Giarola et al., 1998) . Our initial report of APC mutations in aggressive ®bromatosis studied a relatively small number of tumors, and the high incidence found was likely due to a sampling error from examining only this small number. The incidence reported in this series of tumors is closer to that reported by Giarola and colleagues. Taking all of these studies into account, the overall incidence is estimated to be between 15 and 20%.
There are a variety of mechanisms by which betacatenin protein level may be increased in lesions containing neither an APC nor a beta-catenin mutations. This includes secreted Wnt (wingless) protein activating its receptor, or a mutation activat- Figure 4 Confocal microscopy of beta-catenin immunohistochemistry from cells in culture. Cell cultures were derived using mechanical dissociation of cells in DMEM media with 10% fetal calf serum (Alman, 1998) . After a week, the cells were trypsinized and placed into additional culture¯asks containing a cover slip. After an additional week, the cover slips were removed, cells were ®xed in methanol at 48C for 20 min, and immunohistochemistry for beta-catenin performed as for the tissue sections. A FITC labeled secondary antibody was used to detect beta-catenin. The cells were observed under confocal microscopy. Normal ®broblasts, prepared in the same manner, were used as controls. (a) An aggressive ®bromatosis cell showing nuclear localization. This same pattern was observed in cells containing a beta-catenin mutation, an APC mutation, or from cells in which we did not detect mutations in beta-catenin of APC. (b) A normal ®broblast showing cytoplasmic localization. In many of the normal ®broblasts cells there was stronger localization to the cytoplasmic membrane than in this case Figure 5 Western analysis immunoprecipitation using a betacatenin antibody to determine tyrosine phosphorylation status of beta-catenin. The SW480 colon cancer cell line (American Type Culture Collection, Manassas, VA, USA) was used as a control. Protein was extracted in buer (1% Triton-X-100, 150 mM NaC1, 10 mM Tris pH 7.4, 1 mM EDTA, 1 mM EGTA, 0.2 mM Sodium vanadate, 0.2 mM PMSK, 0.5% NP-40), followed by centrifugation to remove insoluble material. Immunoprecipitation was performed using 250 mg total protein with the monoclonal antibody to beta-catenin in the same buer. The solution was incubated at 48C for 1 h, 5 mg of rabbit IgG was added for an additional 30 min, and protein-A-Agarose was added (10 ml, 50%). The resultant pellet was washed, resuspended in buer, and analysed using Western analysis with either antiphosphotyrosine antibody (PY20, Transduction Laboratory) or the beta-catenin antibody. Lanes`A' and`B' are loaded immunoprecipitates from two aggressive ®bromatoses and lane`SW 480' is loaded with immunoprecipitate from the SW480 colon cancer cell line. Western analysis using the PY20 antiphosphotyrosine antibody only detected protein from the SW480 cell line, while the betacatenin antibody (labeled`total protein') detected protein in the aggressive ®bromatoses as well ing another mediator in the cascade. It is possible that such mechanisms are present in the sporadic aggressive ®bromatoses that do not harbor beta-catenin or APC mutations.
The functional signi®cance of tyrosine phosphorylation of beta-catenin is as yet unclear. Evidence from epithelial cell studies suggest that tyrosine phosphorylation occurs at the cell membrane, and that it is associated with increased cell motility (Liu et al., 1997; Takayama et al., 1998) , but it is not yet known if cell motility is abnormal in aggressive ®bromatosis. The lack of tyrosine phosphorylation in aggressive fibromatosis, compared to colonic carcinoma, may be related to the relative lack of beta-catenin at the cell membrane, or perhaps to beta-catenin having dierent binding partners.
Previous transfection studies in primary aggressive ®bromatosis cell culture, which were derived from four of the lesions containing APC mutations reported in this study, suggest that the proliferative advantage held by tumors containing an APC mutation is mediated by beta-catenin protein level (Li et al., 1998) . In a smaller number of lesions (six), we previously used Western analysis to demonstrate that beta-catenin protein level is elevated in aggressive ®bromatosis, regardless of APC mutational status (Alman et al., 1997a) . Betacatenin, therefore, likely plays a key role regulating proliferation in aggressive ®bromatosis. Its localization in the cell nucleus and the absence of its tyrosine phosphorylated form, supports its function as a regulator of transcription, causing the proliferative advantage, in this lesion.
Currently available treatments for aggressive fibromatosis are less than satisfactory, with local recurrence, or complications from adjuvant therapies, being not uncommon outcomes (Plukker et al., 1995) . The demonstration that beta-catenin protein is stabilized in these lesions, suggests blockade of the Wnt-APCbeta-catenin pathway as a potential treatment. As more is learned about the role of mediators in the signaling cascade, and the downstream genes that regulate proliferation, a novel therapeutic approach may be devised, based on blockade of this signaling pathway.
